智飞生物(300122.SZ)：德谷门冬双胰岛素注射液(CA508注射液)获得Ⅲ期临床试验总结报告

Core Viewpoint - The company Zhifei Biological (300122.SZ) announced that its subsidiary, Chongqing Chanan Biopharmaceutical Co., Ltd., has completed the phase III clinical trial summary report for its insulin injection product, CA508, which shows comparable efficacy and safety to the original drug, NovoRapid® [1] Group 1 - The CA508 insulin injection has met the design requirements for efficacy and safety evaluation as per the Clinical Trial Guidelines for Diabetes Drugs and Biological Products [1] - The product demonstrates effectiveness and safety on par with the original NovoRapid® insulin injection [1]